Seattle Flow Your front door to Seattle's startup scene.
Sign in
Stream Events Podcasts Videos Communities
Charlotte Schubert / GeekWire

Icosavax COVID-19 Vaccine Trial Shows Weaker Immune Response Than Expected, Stocks Fall Over 60%

Icosavax reported interim phase 1/2 trial results for its COVID-19 vaccine showing immune responses below expectations, causing its stock to drop over 60%. The company plans to investigate causes for the underwhelming data while remaining committed to its VLP vaccine platform.

IIcosavax
  • Link
  • Report this item
Replying to

No comments yet.

Seattle Flow — Your front door to Seattle's startup scene.

Run by Marcelo Calbucci MC
Send us a link Terms of Service Privacy For AI assistants
© 2026 Seattle Flow. All rights reserved.

Who liked this

Edit history

Seattle Flow

Your front door to Seattle's startup scene.

Seattle's startup scene is scattered across a hundred feeds, newsletters, and calendars. Seattle Flow brings it together: the news, events, podcasts, and people, plus what the community is saying about them. Every link sends you to the source.

Writing about a Seattle founder, fund, or startup? We'll help it get seen. Found a great story we missed? Send it in.

We're in beta and building this with the community. Tell us what you want to see here.

Seattle's startup scene, every day. The news, events, podcasts, and people, plus what everyone's saying about them. We're in beta: send us a story or tell us what you want to see.